Published in Ther Drug Monit on October 01, 2013
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol (2014) 0.92
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol (2014) 0.90
Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol (2014) 0.81
Multigene predictors of tacrolimus exposure in kidney transplant recipients. Pharmacogenomics (2015) 0.80
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clin Pharmacokinet (2017) 0.76
Clinically relevant pharmacogenomic testing in pediatric practice. Clin Pediatr (Phila) (2014) 0.75
IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients. Acta Pharmacol Sin (2017) 0.75
Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature. Front Public Health (2016) 0.75
Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Front Pharmacol (2017) 0.75
Genetic and molecular identification of genes required for female gametophyte development and function in Arabidopsis. Development (2005) 3.14
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol (2013) 2.43
Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc (2011) 2.38
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol (2011) 2.24
Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.18
ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol (2012) 2.14
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care (2010) 2.11
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther (2003) 2.09
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 2.06
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol (2007) 1.92
Minimally invasive video-assisted thyroidectomy: multiinstitutional experience. World J Surg (2002) 1.80
A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet (2009) 1.78
The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost (2004) 1.74
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes (2009) 1.72
Compartmentalization of the inflammatory response during acute pancreatitis: correlation with local and systemic complications. Am J Respir Crit Care Med (2003) 1.69
The European Register of Specialists in Clinical Chemistry and Laboratory Medicine: guide to the Register, version 3-2010. Clin Chem Lab Med (2010) 1.68
Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit (2009) 1.68
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem (2011) 1.64
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther (2006) 1.58
Acute barium intoxication and hemodiafiltration. J Toxicol Clin Toxicol (2003) 1.55
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity (2008) 1.48
Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. J Surg Res (2012) 1.45
Adverse health effects of child labor: high exposure to chromium and oxidative DNA damage in children manufacturing surgical instruments. Environ Health Perspect (2012) 1.44
The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. Nephrol Dial Transplant (2009) 1.43
Intestinal helminths: a clue explaining the low incidence of inflammatory bowel diseases in Subsaharan Africa? Potential benefits and hazards of helminth therapy. Acta Gastroenterol Belg (2007) 1.41
Prolonged unconsciousness in a patient on automated peritoneal dialysis. Eur J Emerg Med (2006) 1.38
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat (2009) 1.34
Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation (2003) 1.31
Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis (2004) 1.28
Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics (2011) 1.27
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care (2010) 1.26
Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics (2014) 1.26
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
The place of liver transplantation in Caroli's disease and syndrome. Transpl Int (2006) 1.23
Associations of urinary cadmium with age and urinary proteins: further evidence of physiological variations unrelated to metal accumulation and toxicity. Environ Health Perspect (2013) 1.22
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics (2013) 1.21
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation (2005) 1.21
Confounders in the assessment of the renal effects associated with low-level urinary cadmium: an analysis in industrial workers. Environ Health (2011) 1.21
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet (2014) 1.19
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics (2010) 1.17
Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation (2002) 1.12
Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. Respir Res (2006) 1.12
High human exposure to cobalt and other metals in Katanga, a mining area of the Democratic Republic of Congo. Environ Res (2009) 1.12
Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett (2006) 1.11
Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol (2009) 1.11
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst (2004) 1.10
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics (2012) 1.09
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics (2011) 1.09
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics (2008) 1.07
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother (2007) 1.07
The threshold level of urinary cadmium associated with increased urinary excretion of retinol-binding protein and beta 2-microglobulin: a re-assessment in a large cohort of nickel-cadmium battery workers. Occup Environ Med (2010) 1.05
Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother (2005) 1.04
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist (2006) 1.03
PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. Br J Haematol (2011) 1.03
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost (2013) 1.02
Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther (2004) 1.02
The BELFRAIL (BFC80+) study: a population-based prospective cohort study of the very elderly in Belgium. BMC Geriatr (2010) 1.01
Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros (2004) 1.01
UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol (2008) 1.01
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res (2005) 1.01
Validation of an ELISA-based screening assay for the detection of amphetamine, MDMA and MDA in blood and oral fluid. Forensic Sci Int (2005) 1.01
Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics (2009) 1.00
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics (2004) 1.00
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol (2012) 1.00
The EC4 European syllabus for post-graduate training in clinical chemistry and laboratory medicine: version 4--2012. Clin Chem Lab Med (2012) 0.99
Crystal structure of a dimeric oxidized form of human peroxiredoxin 5. J Mol Biol (2004) 0.99
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics (2008) 0.97
Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions. Am J Health Syst Pharm (2006) 0.96
Markers of individual susceptibility and DNA repair rate in workers exposed to xenobiotics in a tire plant. Environ Mol Mutagen (2004) 0.95
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics (2010) 0.95
MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther (2006) 0.95
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics (2010) 0.94
Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. Clin Pharmacokinet (2009) 0.94
A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation. J Clin Pharmacol (2011) 0.93
Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob Agents Chemother (2003) 0.93
Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother (2007) 0.93
A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab (2005) 0.93
Reference values and upper reference limits for 26 trace elements in the urine of adults living in Belgium. Clin Chem Lab Med (2013) 0.93
An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem (2007) 0.93